Cancer Program

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Cancer vaccine win restores Wall Street’s faith in Moderna
  Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
  biopharma_dive · 11h ago
• Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
  Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
  biospace · 15h ago
• Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
  As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…
  fiercebiotech · 17h ago
• Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
  If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
  biospace · 1d ago
• Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
  Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
  biospace · 1d ago
• Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
  At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
  biopharma_dive · 1d ago
• STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
  A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
  stat · 1d ago
• Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
  Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win se…
  fiercebiotech · 2d ago
• Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
  The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
  biospace · 2d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 2d ago